Affinity Asset Advisors, LLC Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001773195
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q1 2024 · 87 positions · Total reported value $720.97M · Top-10 concentration 44.6% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 55.3% · 24 new · 29 cut · 20 exited
Active Share (vs S&P 500): 99.9% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q2 2026 → Q3 2026): -12.1% · vs SPY -14.3% · Prev Value $2.08B — last quarter positions weighted by this quarter price moves · ranking
Est. QTD Return (Q3 2026 → newest close): -2.2% · vs SPY -4.3% · Latest Value $2.15B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking
In its Q1 2024 13F filing, Affinity Asset Advisors, LLC disclosed 87 equity positions with a combined reported value of $720.97M. The filing implies a moderately concentrated portfolio: its ten largest positions account for 44.6% of reported value. HoldingsHub classifies the profile as Small / Health Tilt / High Turnover.
The largest disclosed positions as of Q1 2024 were XBI ($66.42M), MRNA ($42.62M), APGE ($39.34M). By sector, the heaviest allocations are Health Care 59.1%, Materials 0.3%. Versus the prior quarter, allocation shifted toward Health Care (+9.5pp) and away from Industrials (-0.5pp), Other (-9.2pp).
Versus the prior quarter, Affinity Asset Advisors, LLC opened 24 new positions, trimmed 29 and fully exited 20, a turnover rate of 55.3% of positions. The portfolio's overlap with the prior quarter was 47% of names.
The largest new positions opened in Q1 2024 were XBI ($66.42M), MRNA ($42.62M), VERA ($20.27M).
Of the 20 positions fully exited versus the prior quarter, the largest were IMGN ($41.65M), CBAY ($25.76M), LIANY ($16.90M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q1 2024)
Fully Exited (vs previous quarter)
- IMGN IMMUNOGEN INC · prev qtr: $41.65M
- CBAY CYMABAY THERAPEUTICS INC · prev qtr: $25.76M
- LIANY LIANBIO ADR · prev qtr: $16.90M
- MRTX MIRATI THERAPEUTICS INC · prev qtr: $5.88M
- DVAX DYNAVAX TECHNOLOGIES CORP · prev qtr: $4.19M
- GPCR STRUCTURE THERAPEUTICS INC · prev qtr: $4.08M
- AZN ASTRAZENECA PLC · prev qtr: $4.04M
- RLAY RELAY THERAPEUTICS INC · prev qtr: $3.30M · history
Insider Transactions (Form 4)
Latest Affinity Asset Advisors, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Affinity Asset Advisors, LLC is an SEC-registered 13F filer based in New York, NY, United States. As of Q2 2026 it reported 108 US equity positions with a combined value of $2.08B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Firm Snapshot
- Headquarters: NEW YORK, NY, United States
- SEC registration: 801-120744 (status: Approved), registered 2021-04-09
- Regulatory AUM (Form ADV): $2.45B as of 2026-07-27
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 2 private funds, of which 1 hedge funds
- Website: affinityadv.com
Portfolio Structure
- 108 positions · $2.08B reported value (Q2 2026)
- Top 10 holdings = 41.7% of reported value
- Largest position: ROIV (ROIVANT SCIENCES LTD) at 6.4%
- Average position size: $19.25M
Sector Tilt
- Health Care 87.6%
- Financials 1.3%
- Materials 0.3%
- (classified holdings cover 89% of value)
Quarterly Activity
- Q2 2026: 19 new, 34 added, 31 reduced, 12 exited
- 24 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
700.00K | $66.42M | 9.21% | New | |
| 2 |
|
400.00K | $42.62M | 5.91% | New | |
| 3 |
|
592.09K | $39.34M | 5.46% | Add | |
| 4 |
|
837.39K | $36.05M | 5.00% | Add | |
| 5 |
|
115.00K | $30.71M | 4.26% | Add | |
| 6 |
|
470.00K | $22.00M | 3.05% | Add | |
| 7 |
|
3.38M | $21.53M | 2.99% | Add | |
| 8 |
|
510.00K | $21.40M | 2.97% | Add | |
| 9 |
|
300.00K | $20.86M | 2.89% | Reduce | |
| 10 |
|
470.00K | $20.27M | 2.81% | New | |
| 11 |
|
2.64M | $20.24M | 2.81% | Add | |
| 12 |
|
1.40M | $19.75M | 2.74% | Hold | |
| 13 |
|
730.49K | $15.58M | 2.16% | Add | |
| 14 |
|
410.00K | $15.55M | 2.16% | Reduce | |
| 15 |
|
817.83K | $13.16M | 1.82% | Add | |
| 16 |
|
82.14K | $12.85M | 1.78% | New | |
| 17 |
|
300.00K | $12.68M | 1.76% | Reduce | |
| 18 |
|
810.25K | $11.91M | 1.65% | Add | |
| 19 |
|
845.61K | $11.90M | 1.65% | Reduce | |
| 20 |
|
150.00K | $11.26M | 1.56% | Reduce | |
| 21 |
|
139.76K | $11.15M | 1.55% | Add | |
| 22 |
|
165.00K | $9.70M | 1.34% | Add | |
| 23 |
|
830.55K | $9.39M | 1.30% | Add | |
| 24 |
|
1.03M | $8.97M | 1.24% | New | |
| 25 |
|
1.03M | $8.55M | 1.19% | Add | |
| 26 |
|
175.00K | $8.40M | 1.17% | Add | |
| 27 |
|
2.50M | $8.25M | 1.14% | New | |
| 28 |
|
225.00K | $7.92M | 1.10% | Add | |
| 29 |
|
10.50M | $7.63M | 1.06% | Add | |
| 30 |
|
286.20K | $6.77M | 0.94% | Add | |
| 31 |
|
1.27M | $6.51M | 0.90% | New | |
| 32 |
|
2.39M | $6.14M | 0.85% | New | |
| 33 |
|
5.10M | $6.07M | 0.84% | New | |
| 34 |
|
40.00K | $5.98M | 0.83% | Add | |
| 35 |
|
1.02M | $5.82M | 0.81% | New | |
| 36 |
|
9.00M | $5.78M | 0.80% | Add | |
| 37 |
|
1.15M | $5.73M | 0.79% | Hold | |
| 38 |
|
80.00K | $5.61M | 0.78% | Reduce | |
| 39 |
|
80.00K | $5.46M | 0.76% | Add | |
| 40 |
|
500.00K | $5.27M | 0.73% | Hold | |
| 41 |
|
250.00K | $5.16M | 0.71% | New | |
| 42 |
|
100.00K | $4.92M | 0.68% | Hold | |
| 43 |
|
26.75K | $4.76M | 0.66% | Add | |
| 44 |
|
144.40K | $4.67M | 0.65% | Reduce | |
| 45 |
|
1.00M | $4.48M | 0.62% | Hold | |
| 46 |
|
65.00K | $4.43M | 0.61% | New | |
| 47 |
|
258.59K | $4.41M | 0.61% | Reduce | |
| 48 |
|
327.96K | $4.23M | 0.59% | New | |
| 49 |
|
50.00K | $4.10M | 0.57% | Reduce | |
| 50 |
|
1.60M | $4.08M | 0.57% | New | |
FAQ
What did Affinity Asset Advisors, LLC buy in 2024-Q1?
In its 2024-Q1 13F filing, Affinity Asset Advisors, LLC reported 87 equity positions worth $720.97M in aggregate; its largest disclosed positions were XBI ($66.42M), MRNA ($42.62M), APGE ($39.34M).
How large is Affinity Asset Advisors, LLC's portfolio?
Affinity Asset Advisors, LLC reported $720.97M of long equity holdings across 87 positions as of 2024-Q1. Top-10 holdings account for 44.6% of reported value.
What is Affinity Asset Advisors, LLC's investment style?
HoldingsHub classifies the portfolio as Small / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.